{"id":"elad-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Coagulopathy"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Device-related complications"}]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ELAD contains human hepatocytes within a bioreactor cartridge that performs synthetic, metabolic, and detoxification functions of the liver when connected extracorporeally. The device bridges patients with acute liver failure toward either spontaneous recovery or transplantation by maintaining critical liver functions and reducing hepatic encephalopathy and other complications of liver failure.","oneSentence":"ELAD is an extracorporeal liver assist device that uses hepatocyte-based bioreactor technology to provide liver support and detoxification functions in patients with acute liver failure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:42.433Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute liver failure (fulminant hepatic failure) as a bridge to transplantation or recovery"}]},"trialDetails":[{"nctId":"NCT01843075","phase":"PHASE2","title":"Evaluating Liraglutide in Alzheimer's Disease","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2014-01","conditions":"Alzheimer's Disease","enrollment":204},{"nctId":"NCT01829347","phase":"PHASE3","title":"To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure","status":"TERMINATED","sponsor":"Vital Therapies, Inc.","startDate":"2014-04","conditions":"Severe Acute Alcoholic Hepatitis","enrollment":18},{"nctId":"NCT01471028","phase":"PHASE3","title":"Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure","status":"COMPLETED","sponsor":"Vital Therapies, Inc.","startDate":"2013-02","conditions":"Acute Alcoholic Hepatitis","enrollment":203},{"nctId":"NCT01875874","phase":"PHASE2","title":"Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)","status":"TERMINATED","sponsor":"Vital Therapies, Inc.","startDate":"2014-10","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function","enrollment":8},{"nctId":"NCT02612428","phase":"PHASE3","title":"Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD","status":"TERMINATED","sponsor":"Vital Therapies, Inc.","startDate":"2016-01","conditions":"Acute Alcoholic Hepatitis","enrollment":151},{"nctId":"NCT00832273","phase":"","title":"Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery","status":"NO_LONGER_AVAILABLE","sponsor":"Vital Therapies, Inc.","startDate":"","conditions":"Liver Failure","enrollment":""},{"nctId":"NCT00771446","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency","status":"COMPLETED","sponsor":"Vital Therapies, Inc.","startDate":"2008-10","conditions":"Acute Hepatitis, Chronic Hepatitis","enrollment":18},{"nctId":"NCT00973817","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis","status":"COMPLETED","sponsor":"Vital Therapies, Inc.","startDate":"2009-09","conditions":"Acute On Chronic Hepatitis","enrollment":62},{"nctId":"NCT00030225","phase":"PHASE2","title":"Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure","status":"COMPLETED","sponsor":"Vital Therapies, Inc.","startDate":"2002-01","conditions":"Fulminant Hepatic Failure","enrollment":19},{"nctId":"NCT00832728","phase":"PHASE2","title":"Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)","status":"WITHDRAWN","sponsor":"Vital Therapies, Inc.","startDate":"2009-03","conditions":"Fulminant Hepatic Failure","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ELAD"],"phase":"phase_3","status":"active","brandName":"ELAD treatment","genericName":"ELAD treatment","companyName":"Vital Therapies, Inc.","companyId":"vital-therapies-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ELAD is an extracorporeal liver assist device that uses hepatocyte-based bioreactor technology to provide liver support and detoxification functions in patients with acute liver failure. Used for Acute liver failure (fulminant hepatic failure) as a bridge to transplantation or recovery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}